Outpatient Monoclonal Antibody (mAb) Therapeutics

As part of the COVID-19 response efforts, Health Resources and Services Administration’s (HRSA) Health Center Program is working in collaboration with Operation Warp Speed (OWS) and State Primary Care Associations (PCAs) to identify health centers to pilot the administration of outpatient monoclonal antibody (mAb) therapeutics to high-risk COVID-19 positive patients in outpatient settings. As of January 4, OWS has reported that 36 health centers have been allocated Bamlanivimab under the SPEED mAb Program in the following 21 states: Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Montana, North Carolina, New Hampshire, New York, Ohio, Pennsylvania, Texas, Wisconsin and West Virginia.

Read more about mAb therapeutics.

What Businesses & Individuals Need to Know About the Latest COVID-19 Stimulus Bill – Encore Presentation

Date: December 31, 2020

Time: 10:00 AM CT

REGISTER

Congress recently passed another COVID-19 emergency relief package as part of an omnibus spending bill. Join BKD as they discuss the tax provisions in this round of stimulus funding, including what’s new for the Paycheck Protection Program, extension and expansion of tax credits for 2021, and other tax-related legislative developments that businesses and individuals should be aware of.

Webinar: NRHC and NARHC Explain the Comprehensive RHC Reform

Date: December 30, 2020

Time: 1:00 PM CT

Register

National Association of Rural Health Clinics (NARHC) will hold a webinar with NARHC Executive Director Bill Finerfrock and National Rural Health Association (NRHA) Government Affairs Director Nathan Baugh explaining the comprehensive Rural Health Clinic (RHC) reform that will impact both independent and Provider-Based RHCs that was included in the COVID-19 relief/appropriations package.

COVID-19 Vaccine Codes: Updated Effective Date for Moderna

On December 18, 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the Moderna COVID‑19 Vaccine for the prevention of Coronavirus Disease (COVID-19) for individuals 18 years of age and older. Review Moderna’s Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) regarding the limitations of authorized use.

During the COVID-19 Public Health Emergency (PHE), Medicare will cover and pay for the administration of the vaccine (when furnished consistent with the EUA). Review the updated payment and HCPCS Level I CPT code structure for specific COVID-19 vaccine information. Only bill for the vaccine administration codes when claims are submitted to Medicare; don’t include the vaccine product codes when the vaccines are free.

Related links:

Webinar: Preparing Your Health Center to Administer Outpatient COVID-19 Monoclonal Antibodies

The Health Resources and Services Administration (HRSA), Operation Warp Speed, and the Food and Drug Administration (FDA) will host a webinar to share information about preparing your health center to administer outpatient COVID-19 monoclonal antibodies (mAbs). What does readiness entail? What staff do I need? How many patients can I serve? Which patients can benefit from mAb? Does our insurance cover this practice? Speakers will answer these and other questions. Speakers from health centers that are already providing infusion therapy, as well as HRSA leadership, will be featured.

Tuesday, December 22
1:00-2:00 p.m. ET
Register here

Eli Lilly and Regeneron both received emergency use authorizations (EUA) from FDA for COVID-19 monoclonal antibodies (mAbs) indicated for at-risk patients with mild to moderate symptoms to reduce disease progression and hopefully prevent hospitalizations. Eli Lilly’s product (bamlanivimab) is a single mAb therapy. Regeneron’s product (casirivimab and imdevimab) is a therapy consisting of two mAbs that must be administered as a single infusion. The Department of Health and Human Services (HHS) is currently allocating both treatments to states/jurisdictions on a weekly basis.

To learn more about how you can prepare your health center for outpatient administration of these products, join this webinar and see the Operation Warp Speed Therapeutics Monoclonal Antibodies Playbook.

HHS Increases and Begins Distributing Over $24 Billion in Phase 3 COVID-19 Provider Relief Funding

December 16, 2020

The Trump Administration, through the Health Resources and Services Administration (HRSA), is announcing it has completed review of Phase 3 applications from the Provider Relief Fund (PRF) program and will distribute $24.5 billion to over 70,000 providers. Up from the $20 billion originally planned, the addition of another $4.5 billion in funding is being used to satisfy close to 90 percent of each applicant’s reported lost revenues and net change in expenses caused by the coronavirus pandemic in the first half of 2020. The U.S. Department of Health and Human Services (HHS) recognizes this pandemic has upended the health care system and caused significant financial hardships. These resources, along with previous distributions, have provided much needed relief. Payment distribution will continue through January, 2021.

Read the news release.

COVID-19 Partner Update December 21, 2020: COVID-19 Response Vaccine Update

Please join the weekly partner call for updates on the COVID-19 response, including new resources for the private sector and the general public.

Date: Monday, December 21, 2020

Time: 2:00—3:00 p.m. CT

CDC Speakers

  1. Dr. Nancy Messonnier, Director of the National Center for Immunization and Respiratory Diseases and Lead for the CDC COVID-19 Vaccine Task Force
  2. Ms. Michelle Putnam, Deputy for Partnerships and Risk Management, CDC COVID-19 Emergency Response (Moderator)

Dr. Nancy Messonnier, Director of the National Center for Immunization and Respiratory Diseases and Lead for the CDC COVID-19 Vaccine Task Force will present. Michelle Putnam, Deputy for Partnerships and Risk Management, CDC COVID-19 Emergency Response, for the Partnership Strategy Unit will moderate. Dr. Messonnier will provide updates on the current status of COVID-19 vaccines.

Please submit your questions by 12/16 so that we can group similar questions and answer as many as possible. Please emaileocevent337@cdc.govwith “Partner Call 12/21” in the subject line.  

Register in advance for this webinar: COVID-19 Response Vaccine Update

The call will be recorded and posted with previous Partner Update webinars here

COVID-19 Vaccine Codes: Updated Effective Date for Pfizer-BioNTech

MLN Connects Special Edition – Monday, December 14, 2020

On December 11, 2020, the U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID‑19 Vaccine for the prevention of COVID-19 for individuals 16 years of age and older. Review Pfizer’s Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) regarding the limitations of authorized use.

During the COVID-19 Public Health Emergency (PHE), Medicare will cover and pay for the administration of the vaccine (when furnished consistent with the EUA). Review our updated payment and HCPCS Level I CPT code structure for specific COVID-19 vaccine information. Only bill for the vaccine administration codes when you submit claims to Medicare; don’t include the vaccine product codes when vaccines are free.

Related links: